原创《新辅助化疗法治疗穿孔型胃癌临床效果》：本论文主要论述了胃癌论文范文相关的参考文献,对您的论文写作有参考作用。
[摘 要] 目的 探讨新辅助化疗法治疗穿孔型胃癌的临床效果.方法 方便选取该院2012年6月—2016年6月期间收治的28例穿孔型胃癌患者的临床资料,将其随机分为对照组和观察组,每组14例.对照组给予常规根治术治疗,观察组给予新辅助化疗法治疗.比较两组治疗效果. 结果 观察组患者肿瘤控制率为85.71%,明显优于对照组的42.86%,不良反应发生率为14.29%,相对低于对照组的42.86%,差异有统计学意义（P<0.05）；观察组1年后患者生存率高于对照组,差异有统计学意义（P<0.05）.结论 新辅助化疗法治疗穿孔型胃癌的临床效果显著,其不仅能够有效地控制肿瘤,还能够降低不良反应发生率,提升患者的生活质量,延长其生存寿命,值得临床重视与推广.
[关键词] 新辅助化疗；穿孔型胃癌；疗效
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2018）02（a）-0090-03
Clinical Study of Neoadjuvant Chemotherapy for Perforated Gastric Cancer
ZHI Li-li
Department of Inner Medicine, Liaocheng Veterans Hospital, Liaocheng, Shandong Province, 252000 China
[Abstract] Objective This paper tries to investigate neoadjuvant therapy in the treatment of gastric cancer perforation. Methods The clinical data of 28 patients with perforation type gastric cancer who were treated in this hospital from June 2012 to June 2016 were convenient selected and randomly divided into control group and observation group with 14 cases in each group. The control group was given conventional radical operation and the observation group was given neoadjuvant chemotherapy. The treatment effect of two groups were compared. Results The tumor control rate of the observation group was 85.71%, which was significantly better than 42.86% of the control group, and the incidence of adverse reactions was 14.29%, which was lower than that of the control group 42.86%, the difference was statistically significant（P<0.05）； the observation group after 1 year survival rate was higher than the control group, the difference was statistically significant（P<0.05）. Conclusion Neoadjuvant therapy in the treatment of gastric cancer perforation is significant, which not only can effectively control the tumor, but also can reduce the incidence of adverse reactions, improve the quality of life of patients, prolong the survival of life, which is worthy of attention and promotion.
[Key words] Neoadjuvant chemotherapy； Keyhole gastric cancer； Curative effect
随着现代人饮食习惯的变化,胃病的发生率也相对提高.胃癌是临床常见的一种消化系统肿瘤,在恶性肿瘤中发病率较高,且致死率也相对高,基本可以占据第二[1].其中穿孔型胃癌也是相对常见,其占据胃癌患者的6%左右[2].穿孔型胃癌具有发病急、病情进展快、预后难度大等多个特点,对患者的威胁极大[3].而对于胃癌的治疗,临床有保守治疗和手术治疗两种策略.由于多数患者在發现胃癌时,已经处于中期或者晚期,癌细胞发生转移,实施手术治疗的意义不大[4-5].故而,选择放化疗是相对可靠的[6].该种治疗方案能够降低其分期,提升根治性切除率[7].新辅助化疗法是在现代医疗技术发展的背景下所提出的一种新型治疗方案,临床运用价值较高.该研究方便选取该院2012年6月—2016年6月期间收治的28例穿孔型胃癌患者使用该种方案的资料加以分析,现报道如下.
1 资料和方法
1.1 一般资料
方便选取在该院收治的28例穿孔型胃癌患者的临床资料,将其随机分为对照组和观察组,每组14例.对照组男8例,女6例,年龄24～71例,平均年龄（42.39±4.28）岁；观察组男7例,女7例,年龄23～72岁,平均年龄（42.37±4.27）岁.临床分期：6例4期、4例3期、4例2期.两组患者一般资料进行比较,其差异无统计学意义（P>0.05）.
胃癌论文参考资料：
结论：新辅助化疗法治疗穿孔型胃癌临床效果为关于胃癌方面的论文题目、论文提纲、胃癌的早期症状有哪些论文开题报告、文献综述、参考文献的相关大学硕士和本科毕业论文。
